Abstract
Fungi are typically opportunistic pathogens. Formerly, limitations in diagnostic techniques explain why invasive fungal infections are usually detected in a late stage of their development. Therefore, traditional guidelines dictate antifungal treatment for all patients with persisting fever. This is not longer justifiable in view of the potential adverse events and the economical burden associated with the use of the new antifungal drugs in an era with improved diagnostic tools. Amphotericin B has been the drug of choice for invasive fungal infections for more than 30 years. Owing to nephrotoxicity, its use in neutropenic patients has been largely abandoned in favor of a lipid formulation of amphotericin B, of which only liposomal amphotericin B has been scientifically tested in the first-line treatment of aspergillosis. Azoles constitute an acceptable alternative to intravenous amphotericin B for many invasive fungal infections.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
We are sorry, but there is no personal subscription option available for your country.
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Pagano L, Caira M, Nosari A, Van Lint MT, Candoni A, Offidani M et al. Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study—Sorveglianza Epidemiologica Infezioni Fungine nelle Empatie Maligne. Clin Infect Dis 2007; 45: 1161–1170.
Blijlevens N, Schwenkglenks M, Bacon P, D’Addio A, Einsele H, Maertens J et al. Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy—European Blood and Marrow Transplantation Mucositis Advisory Group. J Clin Oncol 2008; 26: 1519–1525.
Maertens J, Van Eldere J, Verhaegen J, Verbeken E, Verschakelen J, Boogaerts M . Use of circulating galactomannan for early diagnosis of invasive aspergillosis in allogeneic stem cell transplant recipients. J Infect Dis 2002; 186: 1297–1306.
Donnelly JP . Polymerase chain reaction for diagnosing invasive aspergillosis:getting closer but still a ways to go. Clin Infect Dis 2006; 42: 487–489.
De Pauw BE, Donnelly JP . Prophylaxis and aspergillosis—has the principle been proven? N Engl J Med 2007; 356: 409–411.
Maertens J, Theunissen K, Verhoef G, Verschakelen J, Lagrou K, Verbeken E et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at risk of invasive fungal infection: a prospective feasibility study. Clin Infect Dis 2005; 41: 1242–1250.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
BEdeP has recieved lecture fees from Pfizer Inc., Gilead Sciences, MSD, and Astellas Inc.
Additional information
This article was published as part of a supplement that was supported by Novartis, MSD Italia, Roche, Celgene, GlaxoSmithKline, Sanofi, Gilead, Adienne, Italfarmaco, Pierre Fabre Pharmaceuticals with an unrestricted educational contribution to AREO—Associazione Ricerche Emato-Oncologiche (Genoa) and AMS—Associazione Malattie del Sangue (Milan) for the purpose of advancing research in acute and chronic leukemia.
Rights and permissions
About this article
Cite this article
de Pauw, B. Fungal infections: diagnostic problems and choice of therapy. Leukemia Suppl 1 (Suppl 2), S22–S23 (2012). https://doi.org/10.1038/leusup.2012.14
Published:
Issue Date:
DOI: https://doi.org/10.1038/leusup.2012.14
